Replies to post #45772 on SMART MONEY GROUP

[maytepper]

$SRPT Oppenheimer Maintains Outperform On Sarepta As 3-Year Data Support Eteplirsen's Clinical Benefit http://www.smarteranalyst.com/2014/10/14/oppenheimer-maintains-outperform-sarepta-3-year-data-support-eteplirsens-clinical-benefit/

Here's another one..